Faecal microbiota from patients with cirrhosis has a low capacity to ferment non‐digestible carbohydrates into short‐chain fatty acids

  title={Faecal microbiota from patients with cirrhosis has a low capacity to ferment non‐digestible carbohydrates into short‐chain fatty acids},
  author={Mingliang Jin and Sylvia Kalainy and Nami Baskota and Diana Chiang and Edward C. Deehan and Chelsea McDougall and Puneeta Tandon and Inés Martínez and Carlos Cervera and Jens Walter and Juan G. Abraldes},
  journal={Liver International},
  pages={1437 - 1447}
Cirrhosis is associated with dysbiosis, but its functional consequences are still largely unknown. Short‐chain fatty acids (SCFAs) account for physiological interactions between the gut microbiota and host. Our aim was to assess the impact of cirrhotic dysbiosis on the production of SCFAs. 

Circulating levels of butyrate are inversely related to portal hypertension, endotoxemia, and systemic inflammation in patients with cirrhosis

A global reduction in the blood levels of SCFA in patients with cirrhosis is associated with a more advanced liver disease, suggesting its contribution to disease progression, and an inverse relationship between butyric acid and HVPG values.

Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma

Gut microbiota of patients with liver cancer is disordered, and gut dysbiosis of LC‐HCC and NLC‐H CC is characterized to elucidate the role of GM in the pathogenesis of HCC.

Escherichia/Shigella, SCFAs, and Metabolic Pathways—The Triad That Orchestrates Intestinal Dysbiosis in Patients with Decompensated Alcoholic Cirrhosis from Western Mexico

The gut microbiota of patients with alcohol-decompensated cirrhosis possesses a pathogenic/inflammatory environment; therefore, future strategies to balance intestinal dysbiosis should be implemented.

Gut microbiota modulation with long-chain corn bran arabinoxylan in adults with overweight and obesity is linked to an individualized temporal increase in fecal propionate

This study showed that long-chain arabinoxylan modulates both microbiota composition and the output of health-relevant SCFAs, providing information for a more targeted application of this fiber.

The impact of the gut microbiome on liver transplantation

Although transplant is highly successful with acceptable survival rates, infections, rejection, disease recurrence and death remain important complications andgnostication and interventions involving the gut microbiome could be beneficial.

Effects of Short Chain Fatty Acids (SCFAs) Modulation on Potentially Diarrhea Causing Pathogens in Yaks Through Metagenomics Sequencing

Besides the increased pathogens level of Staphylococcus aureus, Babesia ovata, Anaplasma phagocytophilum, Bacteroides fluxus, viruses, Klebsiella pneumonia, and inflammation-related bacteria; the decreased of SCFAs caused by the imbalance of intestinal microbiota may potentially leads to emergence of diarrhea in yaks.

Promises of microbiome-based therapies.

Dynamic changes of inulin utilization associated with longitudinal development of gut microbiota

Role of the Gut Microbiota in Regulating Non-alcoholic Fatty Liver Disease in Children and Adolescents

This review comprehensively summarizes the current knowledge of the gut microbiota, focusing on its interaction with NAFLD and its potential therapeutic role in obese children and adolescents with this disorder.



Fecal microbiota transplantation in the management of hepatic encephalopathy

It is hypothesized that manipulating the gut microbiome through fecal microbiota transplantation (FMT) could reverse intestinal dysbiosis and result in cognitive improvement in overt HE.

Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: A randomized trial

A randomized, placebo‐controlled trial investigated the effects of rifaximin on inflammation and BT in decompensated cirrhosis and found that intestinal decontamination with rifaxIMin may reduce bacterial translocation and decrease inflammation.

Host-gut microbiota metabolic interactions

Gut Microbiota, whose construction changes all the time, response to external factors together with the human body metabolic balance, which has important significance to the authors' health.

Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function.

Omeprazole is associated with a microbiota shift and functional change in the distal gut in patients with compensated cirrhosis that could set the stage for bacterial overgrowth.

Specific substrate-driven changes in human faecal microbiota composition contrast with functional redundancy in short-chain fatty acid production

Interestingly, butyrate formation was influenced not only by the overall %butyrate-producing bacteria in the community but also by the initial pH, consistent with a pH-dependent shift in the stoichiometry of Butyrate production.

Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy

Rifaximin is associated with improved cognitive function and endotoxemia in MHE, which is accompanied by alteration of gut bacterial linkages with metabolites without significant change in microbial abundance.